Your browser doesn't support javascript.
loading
Association between poor tolerability of antidepressant treatment and brain functional activation in youth at risk for bipolar disorder.
Nery, Fabiano G; Masifi, Sheela L; Strawn, Jeffrey R; Duran, Luis R; Weber, Wade A; Welge, Jeffrey A; Adler, Caleb M; Strakowski, Stephen M; DelBello, Melissa P.
Afiliação
  • Nery FG; Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Masifi SL; Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Strawn JR; Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Duran LR; Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Weber WA; Department of Psychiatry, Dell Medical School, University of Texas at Austin, Austin, TX, USA.
  • Welge JA; Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Adler CM; Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Strakowski SM; Department of Psychiatry, Dell Medical School, University of Texas at Austin, Austin, TX, USA.
  • DelBello MP; Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Braz J Psychiatry ; 43(1): 70-74, 2020.
Article em En | MEDLINE | ID: mdl-32876131
ABSTRACT

OBJECTIVE:

To investigate whether poor antidepressant tolerability is associated with functional brain changes in children and adolescents of parents with bipolar I disorder (at-risk youth).

METHODS:

Seventy-three at-risk youth (ages 9-20 years old) who participated in a prospective study and had an available baseline functional magnetic resonance imaging (fMRI) scan were included. Research records were reviewed for the incidence of adverse reactions related to antidepressant exposure during follow-up. The sample was divided among at-risk youth without antidepressant exposure (n=21), at-risk youth with antidepressant exposure and no adverse reaction (n=12), at-risk youth with antidepressant-related adverse reaction (n=21), and healthy controls (n=20). The fMRI task was a continuous performance test with emotional distracters. Region-of-interest mean activation in brain areas of the fronto-limbic emotional circuit was compared among groups.

RESULTS:

Right amygdala activation in response to emotional distracters significantly differed among groups (F3,66 = 3.1, p = 0.03). At-risk youth with an antidepressant-related adverse reaction had the lowest amygdala activation, while at-risk youth without antidepressant exposure had the highest activation (p = 0.004).

CONCLUSIONS:

Decreased right amygdala activation in response to emotional distracters is associated with experiencing an antidepressant-related adverse reaction in at-risk youth. Further studies to determine whether amygdala activation is a useful biomarker for antidepressant-related adverse events are needed.
Assuntos